Sign in
Active, not recruitingPhase 3

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Key facts

Who runs it
Neurocrine Biosciences
Where
Ann Arbor, Atlanta, Aurora, Birmingham, Boston, Dallas, Hartford, Indianapolis, Los Angeles, Minneapolis, New Hyde Park, New York, Oklahoma City, Orange, Philadelphia, Pittsburgh, San Diego, San Francisco, Seattle, St Louis, Tulsa, and Washington D.C., United StatesSee the 22 sitesAlso in 9 other countries, 18 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
103 people enrolled
Started
25 Jun 2021
Expected to end
Aug 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Crinecerfont
  • Placebo
Record updated
5 February 2025

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Be willing and able to adhere to the study procedures, including all requirements at the study center, and return for the follow-up visit
  • Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency
  • Be on a stable steroid regimen
  • Have elevated androgen levels
  • Participants of childbearing potential must be abstinent or agree to use appropriate birth control during the study

Who cannot take part

  • Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
  • Have current substance dependence or substance (drug) or alcohol abuse
  • Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Have a clinically significant unstable medical condition or chronic disease other than CAH
  • Have a history of cancer unless considered to be cured
  • Have a known history of clinically significant arrhythmia or abnormalities on electrocardiogram (ECG)
  • Have a known hypersensitivity to any corticotropin-releasing hormone antagonist
  • Have a diagnosis of any of the other forms of classic CAH

Where in United States

Also in 9 other countries, 18 sites

  • Ann Arbor, MichiganHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Aurora, ColoradoHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Hartford, ConnecticutHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • New Hyde Park, New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Orange, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Tulsa, OklahomaHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

About the trial

What the trial wants to find out

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric participants with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of open-label treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 14 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

The 2 groups in the trial

  • CrinecerfontTreatment being tested

    Crinecerfont solution or capsule, administered orally, twice daily for 28 weeks during the placebo-controlled treatment period, followed by active treatment with crinecerfont for at least 24 weeks.

  • PlaceboPlacebo, for comparison

    Placebo solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment with crinecerfont for at least 24 weeks.

    Treatment: Crinecerfont and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Publications
Record updated
5 February 2025